Abbmira therapeutics is a Basel based biotech founded by experience scientists and entrepreneurs in September 2024. Abbmira develops first-in-class small molecules to fine-tune native immunity to treat difficult-to-treat cancers and chronic diseases.
Products, services, technology
Our investigational compound42 uses a novel mechanism to target macrophages and repolarizes them towards an anti-tumor state.
Cooperation possibilities
We offer a pre-seed CHF 800K investment opportunity to finance a medchem program to develop lead clinical candidates. Please get in touch with us if you are interested.
- http://www.abbmira.com
- +41 77 462 37 27
- marc@abbmira.com
- Marc Creus
